StockTipsArenaBeta

BUY Mankind Pharma Limited — Rakesh Bansal

BUYMankind Pharma Limited
Mankind Pharma share price target & all analyst calls
○ No entry — the market opened at ₹2,358.50, above the ₹2,330 target

byRakesh BansalHorizon: NA (inferred Swing (≤2wk))26 Oct 2026via CNBC Awaaz.

Entry—No entry — opened past the call
Target₹2,330
Total upside —
Stop loss₹2,250—
Exit—No position was opened
ExpiredNAauction close
Follow Rakesh Bansal for new calls(30% target hit, 233 closed calls)Get alertsWatch MANKIND for new buy/sell callsGet alertsSee 145 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 27 Oct, 4:07 pm IST
10 supporting2 neutral0 opposing
Supports the BUY call (10)

Mankind Pharma shares jump 8% as Q2 profit rises 38% to Rs 716 crore

NewsEt-Markets·27 Oct · today

(opens in new tab)

Mankind Pharma Shares Jump Nearly 8% After Q2 Profit Rises 39%

NewsNdtv-Profit·27 Oct · today

(opens in new tab)

Mankind Pharma Q2 profit rises 38% to Rs 716 crore

NewsEt-Markets·27 Oct · today

(opens in new tab)

Mankind Pharma Q2 profit jumps 39% to ₹712 crore as revenue rises 17%

NewsCnbc-Tv18·26 Oct · yesterday

(opens in new tab)

Mankind Pharma to acquire a majority stake in Armed Cell Therapeutics to enter the CAR-T therapy market.

BSE · Company Update·15 Oct · 2w ago

(opens in new tab)
Neutral / worth noting (2)

Mankind Pharma Q2 Review: Export Momentum Continues; Systematix Maintains 'Hold'; Check Target Price

NewsNdtv-Profit·27 Oct · today

(opens in new tab)

Mankind Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

NSE · Outcome of Board Meeting·26 Oct · yesterday

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Mankind Pharma

All analyst calls on Mankind Pharma

More from Rakesh Bansal

Every call and its outcome